These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

481 related items for PubMed ID: 29522865

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Factors predicting the success of intradetrusor onabotulinum toxin-A treatment in children with neurogenic bladders due to myelomeningocele: The outcomes of a large cohort.
    Danacioglu YO, Keser F, Ersoz C, Polat S, Avci AE, Kalkan S, Silay MS.
    J Pediatr Urol; 2021 Aug; 17(4):520.e1-520.e7. PubMed ID: 33712371
    [Abstract] [Full Text] [Related]

  • 6. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin.
    Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P.
    J Urol; 2005 Sep; 174(3):984-9. PubMed ID: 16094019
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Intravesical Electromotive Botulinum Toxin Type "A" Administration for Management of Urinary Incontinence Secondary to Neuropathic Detrusor Overactivity in Children: Long-term Follow-up.
    Ladi-Seyedian SS, Sharifi-Rad L, Kajbafzadeh AM.
    Urology; 2018 Apr; 114():167-174. PubMed ID: 29229221
    [Abstract] [Full Text] [Related]

  • 10. Botulinum toxin A in the treatment of spinal cord injury patients with refractory neurogenic detrusor overactivity.
    Alvares RA, Silva JA, Barboza AL, Monteiro RT.
    Int Braz J Urol; 2010 Apr; 36(6):732-7. PubMed ID: 21176280
    [Abstract] [Full Text] [Related]

  • 11. Urodynamic Outcomes in Children after Single and Multiple Injections for Overactive and Low Compliance Neurogenic Bladder Treated with Abobotulinum Toxin A.
    Naqvi S, Clothier J, Wright A, Garriboli M.
    J Urol; 2020 Feb; 203(2):413-419. PubMed ID: 31518199
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Botulinum Toxin Type A Therapy: Intravesical Injection or Electromotive Drug Administration.
    Ladi-Seyedian SS, Sharifi-Rad L, Kajbafzadeh AM.
    Urology; 2020 Aug; 142():190-194. PubMed ID: 32437774
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Objective and subjective improvement in children with idiopathic detrusor overactivity after intravesical botulinum toxin injection: A preliminary report.
    Al Edwan GM, Mansi HH, Atta ONM, Shaath MM, Al Adwan R, Mahafza W, Afram KM, Ababneh O, Al Adwan D, Muheilan MM.
    J Pediatr Surg; 2019 Mar; 54(3):595-599. PubMed ID: 29887168
    [Abstract] [Full Text] [Related]

  • 17. [Efficacy of toxin-A Botulinum for treating intractable bladder hyperactivity in children affected by neuropathic bladder secondary to myelomeningocele: an alternative to enterocystoplasty].
    Marte A, Vessella A, Cautiero P, Romano M, Borrelli M, Noviello C, Del Gado R, Parmeggiani P.
    Minerva Pediatr; 2005 Feb; 57(1):35-40. PubMed ID: 15791200
    [Abstract] [Full Text] [Related]

  • 18. Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed.
    Bottet F, Peyronnet B, Boissier R, Reiss B, Previnaire JG, Manunta A, Kerdraon J, Ruffion A, Lenormand L, Perrouin Verbe B, Gaillet S, Gamé X, Karsenty G, Groupe d'Etude de Neuro-Urologie de Langue Française (GENULF) and the committee of NeuroUrology of the French Association of Urology (AFU).
    Neurourol Urodyn; 2018 Jan; 37(1):291-297. PubMed ID: 28431196
    [Abstract] [Full Text] [Related]

  • 19. Long-Term Discontinuation of Botulinum Toxin A Intradetrusor Injections for Neurogenic Detrusor Overactivity: A Multicenter Study.
    Baron M, Peyronnet B, Aublé A, Hascoet J, Castel-Lacanal E, Miget G, Le Doze S, Prudhomme T, Manunta A, Cornu JN, Gamé X.
    J Urol; 2019 Apr; 201(4):769-776. PubMed ID: 30359679
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of the first and repeated intradetrusor injections of abobotulinum toxin A 750 U for treating neurological detrusor overactivity.
    Peyronnet B, Roumiguié M, Castel-Lacanal E, Guillotreau J, Marque P, Rischmann P, Gamé X.
    World J Urol; 2016 May; 34(5):755-61. PubMed ID: 26282099
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.